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ABSTRACT
Background Genomic imprinting is allelic restriction of
gene expression potential depending on parent of origin,
maintained by epigenetic mechanisms including parent
of origin-speciﬁc DNA methylation. Among
approximately 70 known imprinted genes are some
causing disorders affecting growth, metabolism and
cancer predisposition. Some imprinting disorder patients
have hypomethylation of several imprinted loci (HIL)
throughout the genome and may have atypically severe
clinical features. Here we used array analysis in HIL
patients to deﬁne patterns of aberrant methylation
throughout the genome.
Design We developed a novel informatic pipeline
capable of small sample number analysis, and proﬁled
10 HIL patients with two clinical presentations
(Beckwith–Wiedemann syndrome and neonatal diabetes)
using the Illumina Inﬁnium Human Methylation450
BeadChip array to identify candidate imprinted regions.
We used robust statistical criteria to quantify DNA
methylation.
Results We detected hypomethylation at known
imprinted loci, and 25 further candidate imprinted
regions (nine shared between patient groups) including
one in the Down syndrome critical region (WRB) and
another previously associated with bipolar disorder
(PPIEL). Targeted analysis of three candidate regions
(NHP2L1, WRB and PPIEL) showed allelic expression,
methylation patterns consistent with allelic maternal
methylation and frequent hypomethylation among an
additional cohort of HIL patients, including six with
Silver–Russell syndrome presentations and one with
pseudohypoparathyroidism 1B.
Conclusions This study identiﬁed novel candidate
imprinted genes, revealed remarkable epigenetic
convergence among clinically divergent patients, and
highlights the potential of epigenomic proﬁling to
expand our understanding of the normal methylome and
its disruption in human disease.
INTRODUCTION
Genomic imprinting is the epigenetic regulation of
gene expression by parent of origin. DNA methyla-
tion at imprinting control regions (ICRs) is the
most robust and widely studied epigenetic modiﬁ-
cation regulating imprinting. Genomic imprinting
requires resetting of DNA methylation in the
germline and its subsequent resistance to erasure
during the transition from germ cell to early
embryonic development.1 2 While methylation at
ICRs is ubiquitous and permanent, the effects on
DNA methylation and expression of surrounding
genes are dependent on other factors such as tissue
and developmental stage.3
Many imprinted loci were identiﬁed through the
developmental disorders caused by their disruption,
and particularly the discovery of uniparental
disomy and other genetic errors in rare human dis-
orders of imprinting.4 5 But the total number of
imprinted genes is not known. Recent efforts to
identify imprinted genes by murine transcriptome
analysis yielded high numbers of transcripts with
allelic bias.6 However, this observation has been
disputed and may be attributable to various tech-
nical sources of skewed allelic representation in
RNA-seq data7 and, more recently, genome-wide
bisulﬁte sequencing has allowed direct assessment
of allele-speciﬁc methylation;8 taken together, these
observations suggest that our current catalogue of
imprinted genes is approaching completion, with
few novel germline imprints remaining to be dis-
covered (http://igc.otago.ac.nz).9
Many known imprinted genes are regulators of
growth and development, and their expression at
critical developmental times is functionally hemizy-
gous. Therefore, alteration of effective copy
number can cause developmental disorders.10 To
date, eight imprinting disorders (IDs) have been
identiﬁed: Beckwith–Wiedemann syndrome (BWS;
MIM #130659), Silver–Russell syndrome (SRS;
MIM #180860), transient neonatal diabetes
(TND) mellitus (MIM #601410), Prader–Willi syn-
drome (MIM #176270), Angelman syndrome
(MIM #105830), matUPD14-like (Temple syn-
drome) and patUPD14-like syndromes, and pseu-
dohypoparathyroidism 1B (PHP-1B; MIM
#103580). Aetiological mechanisms of IDs include
UPD, copy number variation, mutation of the
expressed copy, or epimutation secondary to or
independent of a predisposing genetic mutation.
A subset of patients with IDs have epimutations
affecting multiple imprinted loci across the genome
(multi-locus methylation disorders or hypomethyla-
tion of imprinted loci (HIL)11). The reported rate
of HIL in BWS is 38% (with ICR2
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hypomethylation), 57% in TND (with PLAGL1 hypomethyla-
tion) and 10% in SRS (with ICR1 hypomethylation).12–14 There
is no standard quantiﬁcation for hypomethylation at the affected
loci, though tissue mosaicism is thought to account for the vari-
ation observed between patients. In some of these disorders, a
shared pattern of methylation derangement can be detected,
and underlying genetic mutations have been identiﬁed;15–18 in
other cases, the cause(s) remain unknown.
In order to identify novel imprinted regions, several groups
have used genome-wide methylation analyses of patients with
UPD and HIL, commonly using the Inﬁnium Human
Methylation27 BeadChip array.19–21 The potential limitations of
this approach include the limited coverage of this array, and the
lack of suitable bioinformatic pipelines to study large methyla-
tion changes in small study cohorts, as currently available pipe-
lines are designed to assess modest DNA methylation changes in
large study cohorts.22–24 To address these limitations, we used
the Inﬁnium Human Methylation450 BeadChip array, and
developed a new analysis pipeline capable of robust analysis of
small study groups with large methylation changes.
Here, we analysed the methylomes of 10 HIL patients with
two clinical presentations (ﬁve BWS and ﬁve neonatal diabetes),
compared with normal controls, and identiﬁed hypomethylated
regions, including three hitherto undescribed candidate
imprinted regions.
MATERIALS AND METHODS
Study population (ethics)
Peripheral blood leucocyte DNA of patients with IDs was assessed
by methylation-speciﬁc PCR (msPCR) at 11 maternally methylated
loci, as described (see online supplementary table S1; the majority
of these patients have been previously reported in Poole et al12).
Those patients with hypomethylation at loci additional to the
primary locus for their presenting disorder were classiﬁed as HIL,
and subgrouped using the epigenetic proﬁles of these 11 maternal
imprinted loci. It was apparent that ﬁve patients with TND and
ﬁve with BWS showed an overlapping pattern of hypomethyla-
tion: TND-HIL samples showed hypomethylation at PLAGL1,
DIRAS, IGF2R and IGF1R differentially methylated regions
(DMRs), with some additional overlap of hypomethylation at
MEST, KCNQ1OT1 and GRB10, and BWS-HIL patients shared
hypomethylation of KCNQ1OT1, PLAGL1, IGF2R and MEST,
with NESPAS and GNAS hypomethylation observed in 2/5
patients. These patients were selected for further analysis to deter-
mine whether they had additional shared hypomethylation
patterns.
All TND-HIL patients were negative for ZFP57 mutations
and BWS-HIL patients negative for NLRP2 mutations. The
ethical approval for the use of these samples was obtained
through the study ‘Imprinting Disorders Finding Out Why?’,
approved by Southampton and South West Hampshire Research
Ethics committee 07/H0502/85 and ‘Mapping clinical and
molecular studies of 6q24 transient neonatal diabetes’ approved
by Wiltshire Research Ethics committee 08/H0104/15.
Control population
Control group 1 (N=221) and control group 2 (N=245)
anonymous batch-matched healthy samples from an unrelated
study were used to generate control methylation proﬁles for the
analysis of TND-HIL and BWS-HIL cases, respectively. Control
group 1 samples were mixed gender and source material, with
198 peripheral blood leucocytes DNA samples derived from
cohort members and their partners and 23 cord blood leuco-
cytes DNA samples from their offspring whereas control group
2 contained 221 peripheral blood leucocyte DNA samples from
female subjects at 18 years of age from an unselected population
birth cohort. Ethical approval was obtained from the Isle of
Wight Local Research Ethics Committee (now named the
National Research Ethics Service, NRES Committee South
Central—Southampton B) for the 18 years follow-up (06/
Q1701/34) and NRES Committee South Central—Hampshire B
(09/H0504/129) for the third generation study.
Validation samples
Methylation array ﬁndings were validated by targeted testing of
DNA and RNA samples. DNA was derived from two hydatidi-
form mole cell lines, peripheral blood leucocytes of 92 anon-
ymised controls, four anonymised normal trios and 34
anonymised individuals diagnosed with Down syndrome, and
patients with IDs: ﬁve TND-HIL, six BWS-HIL, seven SRS–
HIL, one PHP-HIL, ﬁve ZFP57 mutation cases presenting with
TND and nine patients with hypomethylation at only one locus
(two TND with PLAGL1 hypomethylation, two BWS patients
with KCNQ1OT1 hypomethylation, four SRS patients with
ICR1 hypomethylation and one with UPD7mat). These samples
were obtained under the same ethical approval as the study
group and previously reported.12 Nucleic acids (DNA and
RNA) from human embryonic and fetal tissues were obtained
with informed consent and with permission from the
Southampton and South West Hampshire joint Research Ethics
Committee, staged according to the Carnegie classiﬁcation or
foot length.
Array-based methylation analysis
1250 ng of Qubit 2.0 Fluorometer quantiﬁed DNAwas bisulﬁte-
treated using the EZ 96-DNA methylation kit (Zymo Research,
California, USA), following the manufacturer’s standard proto-
col. Genome-wide DNA methylation was assessed by The
Oxford Genomics Centre using the Illumina Inﬁnium
HumanMethylation450 BeadChip (Illumina, Inc., California,
USA). Arrays were processed using the manufacturer’s standard
protocol with multiple identical control samples assigned to each
bisulﬁte conversion batch to assess assay variability and samples
randomly distributed on microarrays to control against batch
effects. The BeadChips were scanned using a BeadStation, and
the methylation level (β value) calculated for each queried CpG
locus using the Methylation Module of BeadStudio software.
Data preprocessing and quality control
A pipeline was developed using the Illumina methylation ana-
lysis (IMA) package within the R statistical analysis environment
(http://www.r-project.org).22 Data from ﬁve TND-HIL and ﬁve
BWS-HIL samples were grouped and run in this pipeline inde-
pendently. Sites were removed that contain any missing values.
All samples met minimal inclusion criteria for analysis, as each
sample had >75% sites with a detection p value <1×10−5. In
all, 216 sites were removed from TND-HIL study and 106 from
BWS-HIL study, as these had detected p value >0.05 in at least
75% of the sample analysed. Among these removed sites, 68 are
common between the two study groups. Initial QC-plots (see
online supplementary ﬁgure S1) for both of the studies showed
that male and female samples clustered together via unsuper-
vised clustering resulting from gender-speciﬁc biases in methyla-
tion level.23 24 Therefore, probes on X and Y chromosomes
were removed to discard any sex bias within the samples. The
number of sites annotated by probe types that were removed by
the initial quality control step is shown in online supplementary
table S2. A total of 76.88% probes remained for the TND-HIL
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analysis and 81.82% remained for the BWS-HIL analysis after
the preprocessing.
The β-values were converted to M-values by logit transform-
ation as M-value increases the cogency of statistical tests for dif-
ferential methylation.25 Quantile normalisation was used to
normalise signal intensities for each probe and reduce inter-
array variation.26
Illumina Human 450 K methylation array uses two different
chemistries, Inﬁnium I and II, to enhance the breadth of cover-
age. Inﬁnium I uses two probes per CpG locus (both methylated
and unmethylated query probes), whereas in Inﬁnium II only
one probe (either methylated or unmethylated) per CpG locus
is required. To correct these differences in the results between
these two chemistries, peak correction was applied.27 No batch
correction was required as all the cases and controls for individ-
ual experiments had been processed in the same batch.
Low sample number differential methylation analysis
Stringent criteria were set to select candidate imprinted
sequences hypomethylated in patients, with p values adjusted
using false discovery rate to ensure statistical robustness.28
Individual CpGs were selected when hypomethylated in patients
compared with controls, with an adjusted p value of
>1.33×10−7, and an M-value between +1 and −1 (equivalent
to 0.26≥β≥0.7) in normal controls. Genes containing two CpGs
meeting these criteria and within <2000 nucleotides were
deemed to be candidate DMRs.
Initially paired t test and one-sample t test were used for stat-
istical analysis; however, these methods did not reveal any
probes meeting our stringent criteria, probably because of the
low sample number. Therefore, we explored the linear model
technique, used for analysis of microarray data,29 which models
the signiﬁcant part of the data and then allows the ﬁtted coefﬁ-
cients to be compared in as many ways as possible. Crawford
and Garthwaite proved that using a larger control group can
produce signiﬁcant statistical results even for a single case pro-
vided that appropriate statistical methods are applied.30
Therefore, for both of the case groups, we used larger numbers
of controls (n>200) against smaller numbers of cases (n=5).
The linear model achieved convincing statistical outcomes from
our pipeline, with efﬁcient identiﬁcation of known and novel
hypomethylated loci for both TND-HIL and BWS-HIL case
groups. Using the same criteria, only one region of hypermethy-
lation was found in TND-HIL and four in BWS-HIL; these
were not further examined as they were not relevant to this
study (data not shown).
Targeted validation testing
msPCR analysis of the 11 maternally methylated loci used previ-
ously described primers and protocols.12 msPCR primers for
candidate loci NHP2L1, PPIEL and WRB are listed in online
supplementary table S3.
Bisulﬁte sequencing
Bisulﬁte-speciﬁc primers were designed to amplify regions of
80–180 nt containing 7–12 CpG dinucleotides, using PyroMark
software V.1.0 (Qiagen). Primer sequences are listed in online
supplementary table S3. Amplicons were generated (Phusion
DNA polymerase New England BioLabs) from two patients and
two controls, ligated into pCR2.1 (Invitrogen); 2 μL of each
ligation was transformed into chemically competent TOP10
cells (Invitrogen). Positive clones were selected on agar plates
supplemented with 40 μg/mL X-gal and 100 μg/mL ampicillin.
Overall, 24 white colonies were selected from each plate and
suspended in 50 μL dH2O prior to denaturation (94°C for
5 min). An amount of 1 μL of the denatured bacterial solution
was used as a PCR template for M13 primer ampliﬁcation
(Phusion DNA polymerase New England BioLabs). These reac-
tions were treated with ExoSAP to degrade remaining primers,
prior to sequencing with M13 forward and reverse primers.
Very similar results were obtained for the two controls and the
two patients; results from only one patient and one control are
presented in the ﬁgures.
Restriction digest sequencing
To determine whether methylation was allele-speciﬁc or restricted
by parent of origin, SNPs were analysed in proximity to DMRs in
DNA from family trios. Heterozygous SNPs were identiﬁed and
their inheritance determined by Sanger sequencing in DNA of off-
spring and parents. To determine methylation status, 200 ng of
offspring DNA was digested before ampliﬁcation with restriction
enzymes BstU1 or Mcrbc (New England Biolabs) according to
manufacturer’s instructions, as described.31
Expression analysis
Coding SNPs were identiﬁed within novel imprinting gene can-
didates WRB and NHP2L1 (rs13230 and rs8779, respectively).
These were used to identify heterozygous samples collected fol-
lowing termination of pregnancy for a non-medical/social
reason at gestational age 8–12 weeks with RNA-matched
samples for a range of tissues (primers listed in online supple-
mentary table S3). Allele-speciﬁc expression was then assessed
in available heterozygous embryonic tissues.
cDNA was prepared with SuperScript III reverse transcriptase
(Invitrogen) from 500 ng embryonic RNA. RT-PCR primers
were designed to detect different isoforms of the candidate
genes (see online supplementary table S3) and were ampliﬁed
using Phusion DNA polymerase (New England BioLabs).
RESULTS
Statistical analysis of 450 K methylation array data
We developed a new analysis pipeline to detect methylation
changes, with stringent selection criteria, capable of robust analysis
of our small epigenetically deﬁned groups (see Materials and
methods section). The pipeline employed the linear modelling com-
monly used for microarray analysis and compared small patient
numbers against a large control group to produce signiﬁcant statis-
tical results.29 30 Using stringent selection criteria, 34 hypomethy-
lated regions were identiﬁed in the BWS-HIL cohort and 21 regions
in TND-HIL (ﬁgure 1, see online supplementary tables S4 and S5).
The hypomethylated regions generated from both groups
included several known imprinted genes (table 1, see online sup-
plementary tables S4 and S5), both within and outside the 11
loci previously assessed in targeted analysis. The p values
observed for known loci were proportionate to the degree of
hypomethylation predicted from msPCR analysis of the patients
groups. This is most clearly demonstrated at the disease-speciﬁc
loci, where the lowest adjusted p value for the TND locus
PLAGL1 was more signiﬁcant in TND-HIL than BWS-HIL
(4.84×10−124 vs 4.39×10−51) (see online supplementary ﬁgure
S2B, supplementary tables S4 and S5) and, conversely, the BWS
locus KCNQ1OT1 had a lower p value in BWS-HIL than
TND-HIL cohort (4.27×10−68 vs 9.47×10−10) (see online
supplementary tables S4 and S5). These p values were consistent
with the degree of hypomethylation detected by targeted testing
(see online supplementary table S1).
To assess the effect of merging patient data on the ability of
the pipeline to detect hypomethylation, we used SNRPN, the
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only locus identiﬁed by msPCR in both patient groups with
hypomethylation of a single patient (see online supplementary
table S1). Using our criteria, hypomethylation of SNRPN was
resolved in the TND-HIL, but not the BWS-HIL cohort where
the hypomethylation was less severe (table 1, see online supple-
mentary table S6). Thus, the pipeline was proved to resolve
moderate hypomethylation in a single individual, validating the
analysis of these hyper-rare patients as a group, rather than
attempting analysis of single patients, which presents signiﬁcant
statistical challenges.
In addition to the known imprinted regions, 23 and 11 novel
candidate DMRs were detected in the BWS-HIL and TND-HIL
cohorts, respectively. Nine of these candidate DMRs were shared
between BWS-HIL and TND-HIL patient groups (table 1). It is
noteworthy that the coverage of probes was broadly higher in
known imprinted genes than novel candidates (eg, 54 in PLAGL1,
267 in KCNQ1 and 73 in MEST, compared with 24 in ERLIN2,
28 in WRB, 23 in NHP2L1 and 13 in LOC728448), reducing the
likelihood of ﬁnding such novel candidates by chance.
Validation of differential methylation region candidates
Candidates were prioritised for follow-up based on prior evi-
dence of allele-speciﬁc methylation in primary cell lines and
hypomethylation in sperm (from Fang et al32) which would be
consistent with maternal imprinting (this eliminated JAKMIP1
and GLP2R). Further inspection highlighted three candidates
(NHP2L1, WRB and PPIEL) where hypomethylation affected
sequence contexts characteristic of imprinted genes (ﬁgures 2
Figure 1 Distribution of known and candidate differentially methylated CpG sites in (A) Beckwith–Wiedemann syndrome (BWS) and (B) transient
neonatal diabetes (TND). In each case, the pie chart to the left shows CpG sites compared between cases and controls (in grey), including those
meeting criteria for differential methylation; the pie chart to the right highlights hypomethylated CpG sites, including those in known
clinically-relevant loci (red), loci reported to be imprinted (pink) and loci not currently reported to be imprinted, that is, candidate loci (blue).
(C) Chromosome ideogram showing the distribution across all autosomes of known and candidate differentially methylated loci. Black dots represent
known imprinted genes that were shown to be hypomethylated in the TND patient group in this study; the green dots represent known imprinted
genes shown to be hypomethylated in the BWS patient group in this study. Red and blue squares correspond to candidate imprinted loci in TND-HIL
and BWS-HIL, respectively. The names of imprinted loci associated with imprinting disorders are displayed next to loci, in black, where they were
detected as hypomethylated in patient samples.
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Table 1 Hypomethylated regions shared between TND-HIL and BWS-HIL patients
BWS TND
Candidate Chr Gene name CpG island Probe region* No. probes† Lowest p value‡ Probe region* No. probes† Lowest p value‡
Novel
candidate DMRs
1 LOC728448/PPIEL No 40 024 971–40 025 411 3 1.47E−18 40 024 971–40 025 232 2 3.09E−22
4 JAKMIP1 Yes 6 107 021–6 107 339 4 2.48E−16 6 107 021–6 107 339 4 5.83E−36
7 SVOPL Yes 138 348 774–138 349 443 3 6.30E−41 138 348 774–138 349 443 3 7.21E−20
9 FANCC Yes 98 075 481–98 075 492 2 8.29E−58 98 075 481–98 075 492 2 7.28E−55
17 GLP2R No 9 729 250–9 729 424 3 3.33E−16 9 729 250–9 729 422 4 1.81E−23
21 WRB Yes 40 757 691–40 758 208 2 2.51E−20 40 757 691–40 758 208 4 6.71E−29
8 LOC728024/ERLIN2 No 37 605 517–37 605 783 4 3.87E−40 37 605 359–37 605 978 6 2.69E−42
18 LOC100130522/PARD6G-AS1 Yes 77 905 355–77 905 947 3 1.01E−19 77 905 298–77 905 947 9 4.38E−71
22 NHP2L1 Yes 42 078 217–42 078 723 6 4.08E−15 42 078 217–42 078 723 6 4.25E−54
Imprinted—not associated with ID 1 DIRAS343 Yes 68 512 539–68 517 273 21 6.69E−31 68 512 539–68 517 273 20 5.45E−64
6 FAM50B20 44 Yes 3 849 235–3 849 818 17 1.70E−18 3 849 272–3 849 818 17 1.64E−39
15 IGF1R45 No 99 408 636–99 409 506 5 2.23E−15 99 408 636–99 409 957 6 1.04E−36
19 ZNF33146 47 Yes 54 040 774–54 058 085 11 1.39E−40 54 040 813–54 058 085 10 9.13E−53
20 L3MBTL48 Yes 42 142 417–42 143 502 13 1.32E−17 42 142 417–42 143 489 18 7.60E−25
Imprinted—associated with ID 6 PLAGL1 Yes 144 328 421–144 329 909 14 1.06E−55 144 328 482–144 329 909 15 1.22E−129
7 MEST Yes 130 130 187–130 133 110 42 6.12E−42 130 130 383–130 133 110 42 1.73E−45
11 KCNQ1 Yes 2 715 837–2 722 258 26 1.14E−73 2 720 463–2 722 119 9 4.86E−13
Datasets from five patients with BWS-HIL and five with TND-HIL were compared with datasets from 245 and 211 batch-matched normal controls, respectively. Probes with M-values between −1 and +1 in controls and relative hypomethylation in patients
with a p value of <1.33E−7 were identified. This subset was further filtered by minimal criteria for a hypomethylated locus, that is, ≥2 hypomethylated probes spaced by <2000 nucleotides. Candidate regions that meet these criteria in both BWS-HIL and
TND-HIL are listed in this table.
*Genome position of most proximal and distal probe fulfilling hypomethylation criteria.
†Number of probes within the locus fulfilling hypomethylation criteria.
‡Minimum p value among probes fulfilling hypomethylation criteria.
BWS, Beckwith–Wiedemann syndrome; DMR, differentially methylated region; HIL, hypomethylation of imprinted loci; ID, imprinting disorder; TND, transient neonatal diabetes.
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Figure 2 DNA methylation and expression analysis of NHP2L1 in patients with Beckwith–Wiedemann syndrome (BWS) and transient neonatal
diabetes (TND). (A) Screengrab from UCSC genome browser representing the NHP2L1 gene and imprinted locus. The subregion highlighted in (B) is
marked by a red double-ended arrow. Small numbers under the screengrab denote the exon numbering as used for expression analysis in (E); red
asterisk indicates the position of the SNP analysed in (E). Note that NHP2L1 is transcription from right to left with respect to genomic orientation.
(B) Divergent DNA methylation between normal controls and patients, detected by methylation array. Solid lines denote M-values (left axis). Dashed
lines represent p values of methylation difference between patients and controls (right axis). Black line represents normal controls; blue lines
represent averaged methylation of ﬁve BWS patients; red lines represent averaged methylation of ﬁve TND patients. (C) Illustrative electropherogram
from methylation-speciﬁc PCR experiment showing difference in DNA methylation between a single patient and control. Amplicons derived from
methylated and unmethylated DNA are marked by red and blue lines, respectively. (D) Summary of bisulﬁte cloning and sequencing experiment
comparing a patient with a normal control. The circles represent CpG dinucleotides within a sequence ampliﬁed after bisulﬁte modiﬁcation, with
ﬁlled and empty circles representing methylated and unmethylated DNA sequences respectively. The number to the right indicates the number of
times the sequence was detected in individual clones. In no case were methylated and unmethylated CpG dinucleotides detected within a single
clone. (E) Allele-speciﬁc expression analysis of NHP2L1. Top electropherogram represents genomic sequencing across rs8779 showing heterozygous
SNP. Lower electropherograms represent sequencing of RT-PCR products from pancreatic cDNA, ampliﬁed from exons 1–4 (biallelic expression) and
2–4 (monoallelic).
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Figure 3 DNA methylation and expression analysis of WRB in patients with Beckwith–Wiedemann syndrome (BWS) and transient neonatal
diabetes (TND). (A) Screengrab from UCSC genome browser, representing the WRB gene and imprinted locus. The subregion highlighted in (B) is
marked by a red double-ended arrow. Small numbers under the screengrab denote the exon numbering as used for expression analysis in (E); red
asterisk indicates the position of the SNP analysed in (E). (B) Divergent DNA methylation between normal controls and patients, detected by
methylation array. Solid lines denote M-values (left axis). Dashed lines represent p values of methylation difference between patients and controls
(right axis). Black line represents normal controls; blue lines represent averaged methylation of ﬁve BWS patients; red lines represent averaged
methylation of ﬁve TND patients. (C) Illustrative electropherogram from methylation-speciﬁc PCR experiment, showing difference in DNA methylation
between a single patient and control. Amplicons derived from methylated and unmethylated DNA are marked by red and blue lines, respectively. (D)
Summary of bisulﬁte cloning and sequencing experiment comparing a patient with a normal control. The circles represent CpG dinucleotides within
a sequence ampliﬁed after bisulﬁte modiﬁcation, with ﬁlled and empty circles representing methylated and unmethylated DNA sequences,
respectively. The number to the right indicates the number of times that sequence was detected in individual clones. In no case were methylated
and unmethylated CpG dinucleotides detected within a single clone. (E) Allele-speciﬁc expression analysis of WRB. Top electropherogram represents
genomic sequencing across rs1060180 showing heterozygous SNP. Lower electropherograms represent sequencing of RT-PCR amplicons in human
fetal tissues as stated.
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and 3, see online supplementary ﬁgure S3A). msPCR on a panel
of 96 anonymised normal control samples showed methylation
levels at all three loci to be stable in the normal population (SD
NHP2L1=0.18, WRB=0.23 and PPIEL=0.22: data not shown).
Analysis of complete hydatidiform mole (no methylation at
maternally imprinted loci) showed complete hypomethylation in
all three loci (data not shown).
DNA methylation at the candidate loci was then conﬁrmed by
msPCR in four of the ﬁve test HIL patients in each cohort
(ﬁgures 2C and 3C; see online supplementary ﬁgure S3C;
online supplementary table S1). For the two other patients,
insufﬁcient DNA remained for further analysis). All showed
hypomethylation of at least one candidate locus: 2/4 TND-HIL
patients were hypomethylated at all 3 loci, while 3/4 BWS-HIL
and 1/4 TND-HIL patients showed hypomethylation at 2–3
loci. We then explored the methylation of these loci in DNA
from further ID patients, including those with and without HIL,
and those with hypomethylation of maternal and paternal DNA.
Four of ﬁve additional TND-HIL patients and ﬁve of six add-
itional BWS-HIL patients had hypomethylation at one or more
loci, thus validating these as regions frequently affected by
hypomethylation in TND-HIL and BWS-HIL patients (see
online supplementary table S1). Less expected was the observa-
tion that NHP2L1, WRB and PPIEL candidate DMRs also
showed hypomethylation in SRS-HIL patients (6/7, 4/7 and 1/7,
respectively) and WRB hypomethylation in 1/1 PHP-HIL
patient. No hypomethylation was observed at any of the loci in
ﬁve patients with ZFP57 mutations nor in nine patients with an
ID affecting only one locus. This suggested that hypomethyla-
tion at these loci was restricted to HIL patients, rather than
being widespread among ID patients.
Additionally, WRB methylation was analysed in 34 anon-
ymised DNA samples from individuals diagnosed with Down
syndrome. In all, 31 samples showed partial hypermethylation
in a ratio consistent with the presence of one additional methy-
lated allele of WRB; two showed partial hypomethylation con-
sistent with one additional unmethylated allele of WRB; and
one showed methylation equivalent to normal controls (see
online supplementary ﬁgure S4). We were unable to conﬁrm the
parental origin of the additional chromosome 21 for these
patients. However, given that 95% of trisomy 21 is of maternal
origin,33 we infer that this ratio of apparent hypermethylation
and hypomethylation, at 31:2 Down syndrome patients
(94%:6%), is consistent with DNA methylation being present
on the maternal allele of WRB.
Parent of origin-speciﬁc methylation were investigated at
NHP2L1 and PPIEL candidate DMRs using methylation-speciﬁc
restriction digest and sequencing. These results were consistent
with maternal inheritance of the methylated allele at both candi-
date DMRs (see online supplementary ﬁgures S5 and S6). To
further demonstrate that DNA methylation was discrete, that is,
concentrated on one allele rather than homogeneously distribu-
ted, we performed bisulﬁte cloning and sequencing of NHP2L1,
WRB and PPIEL DMRs. Amplicons from each candidate region
were cloned and sequenced in two controls and two patients
identiﬁed by msPCR as having hypomethylation. This conﬁrmed
the presence of fully-methylated and fully-unmethylated ampli-
cons in controls, and relative hypomethylation in patient
samples for all three candidate regions (ﬁgures 2D and 3D; see
online supplementary ﬁgure S2D).
Validation of allele-speciﬁc expression
To determine whether the hypomethylation observed at the
three candidate DMRs correlated with allele-speciﬁc expression
of the associated genes, we analysed expression of transcripts in
human foetal nucleic acids. We identiﬁed informative SNPs in
NHP2L1 and WRB in the genomic DNA of 8–12 week embryos
(we could not identify informative coding SNPs in PPIEL).
Matched RNA from multiple tissues was reverse-transcribed and
ampliﬁed by RT-PCR using isoform-speciﬁc primers.
For NHP2L1, monoallelic expression was observed for exon
2–4 speciﬁc transcripts and biallelic expression for exon 1–4
speciﬁc transcripts (ﬁgure 2E) in all tested tissues for four
embryos (data not shown). Biallelic expression of WRB was
observed in the majority of tissues tested with both exon 1–6
and 2–6 speciﬁc transcripts. However, sporadic monoallelic
expression was observed with opposing allelic expression in the
skeletal muscle and aorta of a single embryo (exon 1–6 speciﬁc
primers: ﬁgure 3E), and monoallelic expression in 1/3 adrenal
tissues assayed (exon 2–6 speciﬁc primers; data not shown).
DISCUSSION
The data presented here demonstrate the successful use of
whole genome methylation array technology to explore the
methylome in two rare epigenetically deﬁned cohorts of patients
with IDs characterised by HIL.
Our small cohort size necessitated the development of a new
pipeline capable of robust analysis of small group sizes. While
other statistical analyses could not signiﬁcantly detect hypo-
methylated loci, the linear model we applied in the pipeline,
with the stringent criteria, detected differential methylation
robustly. These loci were validated by the evidence from the
prior partial epigenetic proﬁling of our patient groups and low
p values. Moreover, these p values were proportionate to the
degree of hypomethylation predicted from the known patient
epimutations. This allowed us to use the pipeline conﬁdently to
predict novel imprinted regions.
Consistent with the aim of this study, novel candidate DMRs
were identiﬁed that share several attributes of imprinted genes.
From the nine candidate DMRs identiﬁed, follow-up of three
candidates did not validate hypomethylation in the patients ana-
lysed by 450 K methylation array. These loci showed hypo-
methylation in additional TND-HIL and BWS-HIL patients, but
not in patients with hypomethylation restricted to one primary
locus or in normal controls. Hypomethylation of all loci in indi-
viduals with SRS-HIL and WRB in a PHP-HIL patient expanded
the range of patients observed to have hypomethylation at these
regions. Additionally, allele-speciﬁc methylation and parent-
speciﬁc methylation analysis was consistent with monoallelic
methylation of maternal origin for all three candidate DMRs,
with NHP2L1 and WRB showing evidence of allele-speciﬁc
expression.
It is noteworthy that patterns of hypomethylation were
shared between HIL patients with divergent clinical presenta-
tions. This is a surprising observation, but consistent with a
shared cause of their syndromic presentation. It has become
apparent in recent years that IDs with common phenotypes are
associated with multiple imprinted genes (eg, H19 and
KCNQ1OT1 in BWS, and H19 and chr7 in SRS: refs34 35). It is
also apparent that some patients with HIL have clinical features
inconsistent with their epigenotype.14 36 37 There may be
several reasons for this phenotype–epigenotype divergence, but
the most likely is somatic mosaicism, which is common among
IDs and strongly modiﬁes clinical presentation. It is therefore
possible that common underlying causes, including environmen-
tal insults, primary epimutations and trans-acting mutations,
may cause HIL disorders with highly variable phenotypic fea-
tures. Comprehensive epigenetic proﬁling may be required to
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stratify HIL patients with common epimutation patterns and
seek subtle clinical overlaps. Such stratiﬁcation may support
exome analysis for common genetic causes, and moreover iden-
tify further epimutations that may account for some of their
additional clinical features. It may also be informative to
compare epigenotype patterns among patients of different
genetic aetiologies. In this regard, it is interesting that an epigen-
etic analysis of a patient whose mother had an NLRP7 mutation
showed very limited overlap of affected imprinted genes
(FAM50B) alone with our patients, but some shared hypomethy-
lation of non-imprinted genes which may inform differences in
clinical presentation.38
Of the three candidate imprinted loci described here, none
has a well-deﬁned role in either normal physiology or a disease
process. NHP2L1 is a nuclear protein which plays a role in
pre-mRNA splicing as a component of the U4/U6-U5
tri-snRNP39 and shows evidence of allele-speciﬁc methylation.32
Little is known about the function of PPIEL (pseudogene of
peptidylprolyl isomerase E) but aberrant DNA methylation at
PPIEL has previously been associated with bipolar disorder with
a reported strong inverse correlation between gene expression
and DNA methylation levels of PPIEL.40 WRB encodes a basic
nuclear protein of unknown function and maps to the region
associated with congenital heart disease in Down syndrome.41 42
The clinical relevance of these loci, if any, is unknown. It is pos-
sible that these genes, or any of the others identiﬁed as hypo-
methylated in our study, could be associated additional clinical
disorders beyond the eight IDs currently known in clinical gen-
etics. Cardiac disorders have been reported in 9% of a TND
cohort,13 and it is possible that analysis of further patients will
reveal whether the involvement of this locus is of clinical
signiﬁcance.
There were several potential limitations to our study. First,
whole genome methylation analysis by array is restrictive to the
sequences captured on the array: many more candidate
imprinted regions may have potentially been obtained from
whole genome bisulﬁte sequencing; second, additional HIL
cohorts with other IDs may have provided further candidates;
third, the grouping of disease cases was necessary for statistical
purposes, but may have masked the hypomethylation of less
strongly-affected loci. For the candidate regions that have been
identiﬁed there are further limitations to expression analysis in
the form of low frequency SNPs and potentially imprinted tran-
script identiﬁcation. DNA methylation is only one component
of the cellular machinery of imprinting, and the methylation sig-
nature does not necessarily colocate with the gene(s) under its
control, or as has been observed in the case of the candidate
region PPIEL, not even residing within a CpG island.
Further work is required to exploit the ﬁndings of this study.
The candidate imprinted loci identiﬁed here must be charac-
terised to determine whether their epimutation has any bearing
on clinical features in the context of HIL or in as-yet unde-
scribed ID. These or similar patients may be more comprehen-
sively analysed by whole genome bisulﬁte sequencing to increase
capture of candidate genes. Greater resolution may also be
obtained if a bioinformatic pipeline can be developed for statis-
tically robust analysis of individuals, rather than groups of
patients; indeed, such analysis might be the basis for a compre-
hensive clinical genetic diagnosis of HIL. Analysis of further
patients may support accurate stratiﬁcation of patient groups
with common epigenetic signatures—with or without common
phenotype. This in turn would support the search for candidate
trans-acting gene mutations by exome analysis. Identiﬁcation of
common DNA motifs in hypomethylated loci may also indicate
association with common trans-acting factors (by analogy with
ZFP57), and such motifs would be the focus for cis-acting muta-
tions in IDs. Overall, the potential beneﬁts are disproportionate
to the rarity of the patients being analysed, and may include
novel insight into the basic mechanisms of human epigenetics,
as well as novel loci that may be implicated in many other disor-
ders including Down Syndrome and bipolar disorder.
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